TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05488340: A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

Sponsor: Locus Biosciences · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 318 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$1,764,000

Rescue Site Savings

+$1,176,000

Unlock Full NCT05488340 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05488340 Rescue Dossier →